Stock Report: Medivation Inc. (MDVN) Report Updated: May 20, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
|
|
 |
|
|
|
|
|
|
 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | C  no change |
|---|---|
| Last Week: | C  downgrade |
| Two Weeks Ago: | B no change |
Company Profile
Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule, which is in Phase-III development for the treatment of castration-resistant prostate cancer. Medivation, Inc. has collaboration with Astellas for the development, manufacture, and commercialization of MDV3100 for the treatment of prostate cancer. The company was founded in 2003 and is headquartered in San Francisco, California.
Recent News: Medivation Inc.
| 2012-10-22 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-10-02 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-09-30 07:00:03 | Medivation and Astellas Announce New Data From XTANDI(R) (enzalutamide) Pivotal Study |
| 2012-09-24 07:00:05 | Medivation Effects a 2-For-1 Forward Split of Its Common Stock |
| 2012-09-24 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
ADVERTISEMENT
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio
Most Popular Stocks
Daily Leader Boards
Louis' Weekly Ratings
ADVERTISEMENT